Company Description
Anixa Biosciences, Inc., a biotechnology company, develops therapies and vaccines that are focused on critical unmet needs in oncology.
Its therapeutics programs comprising the development of liraltagene autoleucel, a chimeric endocrine receptor-T cell therapy, a novel form of chimeric antigen receptor-T cell (CAR-T) technology that is focused on treating ovarian cancer.
The company also engaged in the development of a vaccine against breast cancer; and the development of a vaccine discovery program to develop additional cancer vaccines to address intractable cancers, including high incidence malignancies in lung, colon, and prostate.
Its vaccine technologies focus on the discovery of additional retired proteins that may be associated with other forms of cancer.
The company was formerly known as ITUS Corporation and changed its name to Anixa Biosciences, Inc. in October 2018.
Anixa Biosciences, Inc. was incorporated in 1982 and is based in San Jose, California.
| Country | United States |
| Founded | 1982 |
| IPO Date | Jan 1, 1987 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 5 |
| CEO | Amit Kumar |
Contact Details
Address: 3150 Almaden Expressway, Suite 250 San Jose, California 95118 United States | |
| Phone | 408 708 9808 |
| Website | anixa.com |
Stock Details
| Ticker Symbol | ANIX |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | November - October |
| Reporting Currency | USD |
| CIK Code | 0000715446 |
| CUSIP Number | 03528H109 |
| ISIN Number | US03528H1095 |
| Employer ID | 11-2622630 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Amit Kumar Ph.D. | Chief Executive Officer, Chairman and Co-Chair of CBAB |
| Michael J. Catelani CPA, MBA | President, Chief Operating Officer, Chief Financial Officer and Corporate Secretary |
| Dr. Pamela D. Garzone Ph.D. | Chief Development Officer and Chair Breast Cancer Clinical Advisory Board |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jan 12, 2026 | S-8 | Securities to be offered to employees in employee benefit plans |
| Jan 12, 2026 | 10-K | Annual Report |
| Jan 6, 2026 | SCHEDULE 13D/A | Filing |
| Dec 12, 2025 | 8-K | Current Report |
| Sep 30, 2025 | EFFECT | Notice of Effectiveness |
| Sep 10, 2025 | S-3 | Registration statement under Securities Act of 1933 |
| Sep 10, 2025 | 10-Q | Quarterly Report |
| Jun 6, 2025 | SCHEDULE 13D/A | Filing |
| May 28, 2025 | 10-Q | Quarterly Report |
| Mar 21, 2025 | 8-K | Current Report |